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Chondroitin sulfate proteoglycansPharmacological inhibitors of epidermal growth factor receptor (ErbB1) attenuate the ability of CNS myelin to
inhibit axonal regeneration. However, it has been claimed that such effects aremediated by off-target interactions.
We have tested the role of ErbB1 in axonal regeneration by culturing neurons from ErbB1 knockout mice in the
presence of various inhibitors of axonal regeneration: CNS myelin, chondroitin sulfate proteoglycans (CSPG),
ﬁbrinogen or polyinosinic:polycytidylic acid (poly I:C). We conﬁrmed that ErbB1 was activated in cultures of cer-
ebellar granule cells exposed to inhibitors of axonal regeneration and that ErbB1 kinase inhibitors promoted
neurite outgrowth under these conditions. In the presence of myelin, ﬁbrinogen, CSPG and poly I:C ErbB1 −/−
neurons grew longer neurites than neurons expressing ErbB1. Furthermore, inhibitors of ErbB1 kinase did not
improve neurite outgrowth from ErbB1−/− neurons, ruling out an off-target mechanism of action. ErbB1 kinase
activity is therefore a valid target for promoting axonal elongation in the presence of many of the molecules
believed to contribute to the failure of axonal regeneration in the injured CNS.
© 2012 Elsevier Inc. Open access under CC BY license. Introduction
Axons do not normally regenerate in the adult mammalian CNS.
Conditions such as complete spinal cord injuries therefore result in
permanent and very serious functional deﬁcits. There are many potent
inhibitors of axonal regeneration in the injured CNS including myelin-
associated proteins, CSPG, ﬁbrinogen and axonal guidance molecules.
These are believed to combine to make the damaged spinal cord very
unfavourable for axon regrowth (Anderson et al., 2007; Bolsover et al.,
2008; Busch and Silver, 2007; Sandvig et al., 2004; Tang, 2003; Verma
and Fawcett, 2005; Wehrle et al., 2005). The EGF receptor ErbB1 may
play an important role in regulating axonal regeneration. In some stud-
ies, stimuli that increase ErbB1 phosphorylation have been shown to
promote axon outgrowth (Evangelopoulos et al., 2009; Goldshmit
et al., 2004; Tsai et al., 2010). However, other studies indicate that
ErbB1 may be a critical mediator of outgrowth-inhibitory cues in the
adult CNS. Exposure to Nogo-66 or OMgp (inhibitory components of
CNS myelin) or CSPG, causes phosphorylation of ErbB1 in an intracellu-
lar calcium-dependent manner (Koprivica et al., 2005). Inhibitors ofhondroitin sulfateproteoglycans;
R3, Toll-like receptor 3.
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se. ErbB1 kinase activity allow axons to grow over an inhibitory substrate
of myelin or CSPG in vitro and through a crush injury of the optic nerve
in vivo (Koprivica et al., 2005). Fibrinogen, which enters CNS lesions
after trauma, acts through β3 integrin to cause ErbB1 phosphorylation;
axon outgrowth is inhibited but can be rescued by application of an
ErbB1 kinase inhibitor (Schachtrup et al., 2007). Axon outgrowth over
ﬁbroblasts is enhanced by treatment with ErbB1 inhibitors (Povlsen
et al., 2008). Inhibiting ErbB1 kinase activity greatly enhanced axonal
regeneration through a crush injury of the mouse optic nerve in vivo
(Koprivica et al., 2005) and it has been reported that treatment with an
ErbB1 kinase inhibitor enhanced functional recovery following spinal
injury in rats (Erschbamer et al., 2007). However, an attempt at replica-
tion of the latter ﬁnding on spinal injury was not successful (Sharp
et al., 2012). These results therefore suggest a model in which a large
number of clinically important inhibitors of CNS axonal regeneration
activate ErbB1, and the activated ErbB1 in some way acts to reduce or
even eliminate axon outgrowth or regeneration. Since the inhibitors of
ErbB1 that have been shown to enhance axonal regeneration include
the licensed drug Erlotinib, these observations have potentially important
clinical applications.
However, experiments using siRNA to knock down ErbB1 expres-
sion in vitro have yielded results inconsistentwith this growing consen-
sus. Cultures in which ErbB1 expression had been dramatically reduced
by treatment with siRNA showed undiminished inhibition of axon out-
growth by myelin, and the ErbB1 kinase inhibitor AG1478 retained its
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it was suggested that AG1478 exerted its axon-promoting effect
through an action on a protein other than ErbB1 (Ahmed et al., 2009;
Douglas et al., 2009). However, siRNA rarely eliminates the target pro-
tein completely. We therefore re-examined this question by using neu-
rons from ErbB1 knockout mice in which the protein is completely
absent. If PD168393 and AG1478 attenuate the effects of inhibitors of
CNS axonal regeneration in these neurons, then theywould be certainly
acting off-target. However, we saw no such protection. Rather, our
results conﬁrm the central role of ErbB1 in mediating the inhibition.
In additionwe sought to examinewhether the nucleic acids can also
inhibit axonal growth through ErbB1. Double stranded RNA and its
analogue poly I:C, acting upon Toll-like receptor 3 (TLR3), have been
reported to inhibit axon outgrowth from sensory neurons (Cameron
et al., 2007). TLR3 may be activated by RNA released from damaged
mammalian cells (Kariko et al., 2005), or by viral RNA. We asked
whether this dramatically different cue also operated through ErbB1
and whether this effect, like that of CNS myelin, involved changes of
intracellular calcium.
Materials and methods
ErbB1 +/− mice were obtained from the Jackson Labs (Strain
Egfrtm1Mag/J) and maintained in a CD1/MF1 mixed outbred colony.
Genotyping used primers and PCR conditions suggested by Jackson
Labs, speciﬁcally the common primer 5′GCCCTGCCTTTCCCACCAT
A3 ′, the mutant-speciﬁc primer 5′TTGCAGCACATCCCCCTTTC3 ′
generating a 450 bp amplicon and the wild type speciﬁc prim-
er 5′ATCAACTTTGGGAGCCACAC3′ generating a 350 bp amplicon.
Genotypingwas performed in the UCL Sequencing and Genotyping Facil-
ity and gave unequivocal results (Supplementary Fig. 1A). ErbB1 −/−
pups were recognised at birth by their open eyes and at later days by
lack of hair. All pups used for dissectionwere genotyped to conﬁrm iden-
tiﬁcation.Westernblots of brains dissected fromE18.5 embryos identiﬁed
as ErbB1 −/− conﬁrmed the absence of the protein (Supplementary
Fig. 1B).
To culture cerebellar granule neurons (CGNs), cerebella were
dissected from humanely killed P5–P7 pups and minced manually
followed by digestion with 0.05% trypsin for 12 min at 37 °C in
phosphate buffered saline. Digestion was terminated by adding excess
foetal bovine serum. The suspension was centrifuged and the pellet
resuspended in 2000 units/ml DNAase (Invitrogen) in Neurobasal
medium (Invitrogen). After trituration large pieces were allowed to
settle and removed; the suspension was then centrifuged and the pellet
resuspended in growthmedium comprisingNeurobasalmediumplus 2%
B27 supplement, 0.4 mM additional glucose, 20 mM additional KCl,
20 μM glutamine, 100 units/ml penicillin and 100 μg/ml steptomycin
followed by plating in 24 well plates at 65,000 cells per well.
Sensory neuron cultures used a growth medium of F12 with
Glutamax (Invitrogen) supplemented with 100 units/ml penicillin
and 100 μg/ml streptomycin and either 10% foetal calf serum or,
where noted, 1% N2 supplement (Invitrogen). Dorsal root ganglia
from P7–P9 pups were dissected and incubated in a mixture of colla-
genase (5 mg/ml), dispase (2 mg/ml) and DNAase (1000 U/ml) for
40 min at 37 °C. The enzyme reaction was stopped by addition of
excess growth medium. The cells were then centrifuged for 10 min
at 1000 rpm. After centrifugation, the supernatant was discarded
and 1 ml of growth medium was added, triturated and centrifuged
for 5 min at 400 rpm. The resultant supernatant was discarded and
1 ml of growth media was added and triturated to form the cell
suspension. In order to reduce the number of non-neuronal cells, a
BSA cushion (15%) was prepared in growth medium. The cell suspen-
sion was slowly added through the sides of the tube such that the
suspension rested on the BSA solution. It was then centrifuged at
1000 rpm for 10 min. The neuronal cells formed the pellet at the
bottom of the tube and the non-neuronal cells were seen as a whitelayer at the interface. The pellet was then resuspended in growth
medium and plated in eight chambered glass slides (VWR).
Substrates were primed by treatment with poly-L-lysine (Sigma,
100 μg/ml overnight). An inhibitory myelin substrate for sensory
neuron culture was prepared by incubating primed slides for 4 h
with myelin (100 μg/ml) followed by incubation for 2 h with 2 μg/ml
laminin. In all other preparations, primed substrates were incubated for
4 h with laminin (10 μg/ml for CGNs, 2 μg/ml for sensory neurons)
mixed where appropriate with myelin or CSPG (100 μg/ml and 5 μg/ml
respectively). In contrast the inhibitory agents ﬁbrinogen and poly I:C
were added to the growth medium.
Cerebellar granule cell cultureswereﬁxedwith 4%paraformaldehyde
after 16 h, whilst sensory neurons were ﬁxed after 24 h (48 h for
cultures onmyelin). Cultureswere stained for neuron-speciﬁcβ3 tubulin
(rabbit polyclonal, Sigma) and with Hoechst 33342 (Sigma). Images
were acquired using a Zeiss Axiophot microscope, Hamamatsu C4742
camera and Improvision software. The total neurite length for each
imaged neuron was measured using the Neurite Tracer plug-in for the
ImageJ software package. For cerebellar granule cells, neurite lengths
on one individual cover slip (10 images at 20× magniﬁcation) were
averaged to yield a single value. In most experiments statistical assess-
ment was performed on measurements obtained from 2 coverslips
from each of 3 animals (N=6). For sensory neurons, neurite lengths
from all four wells with the same culture conditions, comprising
measurements of more than 30 sensory neurons, were averaged to
yield a single value from each animal.
Data from each experiment were analyzed by ANOVA followed by a
set of post tests using Bonferroni correction. These comprised three
types of comparison. First, for each culture environment, neurite out-
growth from ErbB1 knockout neurons was compared with outgrowth
from heterozygote neurons under the same culture conditions. Second,
neurite outgrowth in experimental conditions was compared with out-
growth from neurons of the same genotype under control conditions.
Lastly to assess whether a drug treatment gave signiﬁcant rescue of
neurite outgrowth, neurite length in the presence of a neurite out-
growth inhibitor and additional drugwas comparedwith neurite length
of the same genetic typewith the sameoutgrowth inhibitor butwithout
the drug.
Phosphorylation of ErbB1 in cerebellar granule cells was assessed by
scraping cells off the substrate, washing twice with phosphate buffered
saline, and lysing for 45 min at 4 °C in CelLytic lysis buffer (Sigma
Aldrich) supplemented with 1% protease inhibitor (Sigma) and 1%phos-
phatase inhibitor (Active Motif). Total protein extracts (10 μg/lane)
were separated electrophoretically in 7% Tris-Acetate gel and transferred
to an Immobilon membrane (Millipore). Immunodetection used rabbit
primary antibodies against total and Y1068 phosphorylated EGFR
(1:1000, Cell Signaling, Beverly, Massachussetts) together with mono-
clonal anti-tubulin (1:3000, Sigma). Finally, the primary antibodies
were probed with horseradish peroxidase conjugated polyclonal goat
antibodies (Cell Signaling) for chemiluminescence detection with the
ECL System (GE Healthcare).
ErbB1 inhibitors PD168393 and AG1478 were obtained from
Merck. BAPTA-AM and BCECF-AM were from Invitrogen.
Results
ErbB1 phosphorylation in the presence of the inhibitors of axonal
regeneration, CNS myelin or ﬁbrinogen
First we conﬁrmed that CNSmyelin and ﬁbrinogen, potent inhibitors
of axonal regeneration, elevated levels of ErbB1 phosphorylation.
Phosphorylation of ErbB1 was detectable in cerebellar granule neurons
on a permissive polylysine/laminin substrate, but was markedly in-
creased in cells cultured in the presence of ﬁbrinogen or cultured on
CNSmyelin. As expected, under all conditions, the ErbB1 kinase inhibitor
PD168393 at 10 nM or 100 nM reduced ErbB1 activation to trace levels
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activation of ErbB1 by myelin proteins and ﬁbrinogen (Koprivica et al.,
2005; Schachtrup et al., 2007) and show that such activation persists
during many hours of culture.Both inhibition of ErbB1 and its genetic deletion enhance axonal
regeneration in the presence of CNS myelin, chondroitin sulphate
proteoglycans (CSPG), and ﬁbrinogen
To investigate the role of ErbB1 in regulating neurite outgrowth in
the absence of inhibitors of axonal regeneration we plated cerebellar
granule neurons onto a substrate of polylysine plus laminin. Under
these outgrowth-permissive conditions, we found no consistent
effect on neurite outgrowth by the absence of ErbB1 or by treatment
with its inhibitor PD168393 (Fig. 2A). CNS myelin is known to inhibit
neurite outgrowth from many types of neurons (Caroni and Schwab,
1988; Chivatakarn et al., 2007; McKerracher et al., 1994). PD168393
was reported to rescue neurite outgrowth from retinal ganglion
cells and DRG neurons in the presence of myelin (Ahmed et al.,
2009; Koprivica et al., 2005). We conﬁrmed that rat CNS myelin
prepared in our laboratory inhibited neurite outgrowth and that this
effect was relieved by PD168393. For both cerebellar granule neurons
and primary sensory neurons, myelin dramatically inhibited neurite
outgrowth from ErbB1-expressing cells and this inhibition was
partially rescued by PD168393 at 10 nM or 100 nM (Fig. 2). Neurite
outgrowth from ErbB1 −/− cerebellar granule neurons was
inhibited by myelin, but to a signiﬁcantly smaller extent than seen
with ErbB1-expressing neurons, and the residual inhibition was not
rescued by PD168393 (open bars in Fig. 2A).
Since different neurons use different receptors to detect inhibitors
of neurite outgrowth (Giger et al., 2008) we also studied neurite
outgrowth from ErbB1-expressing primary sensory (DRG) neurons.
Neurites of ErbB1 −/− sensory neurons grown on a myelin substrate
were signiﬁcantly longer than were neurites of ErbB1-expressing
neurons, although not as extensive as when myelin was absent, and
PD168393 did not increase the neurite length of ErbB1 −/− neurites
on this substrate (Figs. 2C, D — note change of scale in some panels).
Hence the absence of ErbB1 or its inhibition by PD168393 signiﬁcantly
disinhibits neurite outgrowth from both cerebellar granule cells and
primary sensory neurons cultured on CNS myelin. It has been claimed
that the effects of ErbB1 inhibitors on axonal outgrowth in the presence
of myelin are off-target, i.e. mediated by effects on a target other than
ErbB1. If that hypothesis were correct then PD168393 should enhance
neurite outgrowth on CNS myelin even in ErbB1−/− cultures. In fact,
neurite outgrowth from ErbB1 −/− cerebellar granule cells and DRGFig. 1. Tyrosine 1068 phosphorylation in ErbB1. Cerebellar granule cells were grown on the
harvested after 16 h. Transfer membranes were probed with an antibody speciﬁc for ErbB1
myelin or ﬁbrinogen but was minimal when PD168393 was added.neurons on CNS myelin was not improved by PD168393 (open bars in
Figs. 2A, C).
CSPG are extracellular matrix and cell surface proteins known to
markedly inhibit neurite outgrowth from a wide range of neurons
(Fitch and Silver, 2008; Snow et al., 1990), and PD168393 was reported
to rescue neurite outgrowth from retinal ganglion cells in the presence
of CSPG (Koprivica et al., 2005). CSPG dramatically inhibited neurite
outgrowth from ErbB1-expressing cerebellar granule cells and this
inhibition was partially rescued by PD168393 at 10 nM or 100 nM
(solid bars in Fig. 3A). Neurite outgrowth from ErbB1 −/− neurons
was inhibited by CSPG, but to a signiﬁcantly smaller extent than seen
with ErbB1-expressing neurons (Fig. 3B), and the residual inhibition
was not rescued by PD168393 (hollow bars in Fig. 3A).
We also studied neurite outgrowth from ErbB1-expressing primary
sensory (DRG) neurons. As expected, outgrowth was dramatically
inhibited by the inclusion of CSPG in the substrate (Fig. 3D). For this
neuronal type, PD168393 eliminated the inhibition (solid bars in
Fig. 3C). In contrast, neurite outgrowth from ErbB1−/− DRG neurons
was not inhibited at all by CSPG at the concentration we used, and
PD168393 did not increase their length (open bars in Fig. 3C). Hence,
the absence of ErbB1 or the presence of the ErbB1 kinase inhibitor
PD168393 disinhibits neurite outgrowth from both cerebellar granule
cells and sensory neurons grown on CSPG. If the effects of ErbB1
inhibitors on axonal outgrowth in the presence of CSPG were off-
target, i.e. mediated by effects on a target other than ErbB1, then
PD168393 should enhance neurite outgrowth on CSPG even in
ErbB1−/− cultures. In fact, neurite outgrowth from ErbB1−/− cere-
bellar granule cells and DRG neurons on CSPG was not improved by
PD168393 (open bars in Figs. 3A, C).
The blood–brain barrier normally precludes contact of CNS neurons
with the blood protein ﬁbrinogen, but at injury sites ﬁbrinogen perme-
ates into the central nervous system tissue. Fibrinogen inhibits neurite
outgrowth from sympathetic neurons and cerebellar granule neurons,
and this outgrowth can be rescued by PD168393 (Schachtrup et al.,
2007). We conﬁrmed this ﬁnding for ErbB1-expressing sensory neurons
and cerebellar granule neurons (Fig. 4). In contrast, neurite outgrowth
from ErbB1−/− neurons of either type was unaffected by ﬁbrinogen at
0.5 μg/ml (Fig. 4) (although ﬁbrinogen at 1.5 μg/ml gave a slight but
statistically signiﬁcant inhibition, data not shown). The reversible ErbB1
inhibitor AG1478 has been reported, like PD168393, to rescue neurite
outgrowth on inhibitory substrates (Douglas et al., 2009; Koprivica
et al., 2005). AG1478 rescued outgrowth from ErbB1-expressing neurons
in the presence of ﬁbrinogen but was without effect on ErbB1 −/−
neurons (Supplemental Fig. 2). Hence the genetic deletion of ErbB1 disin-
hibits neurite outgrowth from both cerebellar granule cells and primary
sensory neurons cultured in the presence of ﬁbrinogen. AG1478 alsoindicated substrates with and without PD168393 at the indicated concentrations and
phosphorylated on Y1068. ErbB1 kinase activity was increased by the presence of CNS
Fig. 2. PD168393 rescues outgrowth on myelin from ErbB1-expressing neurons but does not affect ErbB1 −/− neurons. A: Heterozygous and ErbB1 −/− cerebellar granule cells were
cultured on a control substrate or on amyelin substrate, in the presence of PD168393 at the indicated concentrations. N=6. TwowayANOVApost hocBonferroni, *=pb0.05when compared
to heterozygous cells onmyelin unless shown otherwise, #= pb0.001 when compared to heterozygous cells on a control substrate. B: Representative images of cultured cerebellar granule
neurons from an ErbB1−/− pup and heterozygote littermates on polylysine/laminin substrates with or without myelin ﬁxed and stained for neuron-speciﬁc β3 tubulin. Neurons are indi-
catedwith arrows in the topmiddle panelwhere theywould otherwise be difﬁcult to distinguish from theﬂuorescentmyelin fragments. The ErbB1 kinase inhibitor PD168393was present at
10 nMwhere indicated. Images were taken at ×20 magniﬁcation and scale bar equals 100 μm. The scale bar applies to all panels. C: Heterozygous and ErbB1−/− sensory neurons were
cultured on a myelin substrate in the presence of PD168393 at the indicated concentrations. Neurite length was normalised to the measurement for heterozygous cells on myelin. N=7.
Two way ANOVA post hoc Bonferroni ** = pb0.01 when compared to heterozygous cells under the same culture conditions, # = pb0.05 when compared to heterozygous cells cultured
on myelin. D: Representative images of cultured sensory neurons from an ErbB1 −/− pup and heterozygote littermates on polylysine/laminin substrates with or without myelin ﬁxed
and stained for neuron-speciﬁc β3 tubulin. The ErbB1 kinase inhibitor PD168393 was present at 10 nMwhere indicated. Note the different scales in two of the panels.
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these ﬁndings show that three of the most important factors
inhibiting neurite outgrowth at lesion sites in the central nervous
system exert much of their effect through ErbB1, and that all the
rescue of outgrowth seen when the drugs PD168393 or AG1478 are
applied is due to the effect of these drugs in blocking the action of
ErbB1.
ErbB1 and calcium signalling are involved in the inhibition of axonal
outgrowth by synthetic double stranded RNA
Viral infections during pregnancy are now believed to be important
sources of brain abnormalities and subsequent behavioural problems.
Much of this effect is due to activation by double stranded viral RNA
of Toll-like receptor 3 (TLR3) on both neurons and immune system
cells as part of the defence mechanism against viral infections (Brown
and Derkits, 2010; Dafﬁs et al., 2008; De Miranda et al., 2010; Meyer
et al., 2008; Takeda and Akira, 2007). Activators of TLR3, either double
stranded RNA itself or the artiﬁcial analogue poly I:C, have been
reported to be potent inhibitors of neurite outgrowth from embryonic
mouse or chick sensory neurons (Cameron et al., 2007). Since TLR3
exerts at least part of its effect in non-neuronal cells via activation ofErbB1 (Koff et al., 2008) we examined whether the inhibitory effect
on neurite outgrowth, like that of myelin, CSPG and ﬁbrinogen, acted
through ErbB1. We ﬁrst conﬁrmed that poly I:C is a potent inhibitor of
axonal regeneration in vitro. Measurements of neurite outgrowth
showed a very similar pattern with poly I:C as with CSPG and ﬁbrino-
gen: ErbB1-expressing neurons were inhibited by poly I:C at 100 μg/
ml and rescued by PD168393, whilst ErbB1−/− neurons are unaffect-
ed by poly I:C (Figs. 5A–D). Once again, the absence of effects of
PD168393 on ErbB1−/− cultures showed that off-target effects were
not involved. Buffering of intracellular calcium changes was reported
to prevent the activation of ErbB1 otherwise affected in cerebellar gran-
ule cells by exposure to myelin (Koprivica et al., 2005). To examine
whether the ErbB1- dependent inhibition of neurite outgrowth by
poly I:C is similarly dependent on intracellular calcium signals, we
performed outgrowth assays in the presence of the cell permeable cal-
cium buffer BAPTA-AM. Signiﬁcant rescue of neurite outgrowth from
ErbB1-expressing sensory neurons was seen in the presence of
100 nM BAPTA-AM (solid bars in Fig. 5E). In contrast BCECF-AM, a pH
buffer which utilises the same esterase reactions to enter cells, was
without effect. As expected, BAPTA-AM did not improve neurite out-
growth from ErbB1 −/− neurons on any substrate (open bars in
Fig. 5E).
Fig. 3. PD168393 rescues outgrowth from ErbB1-expressing neurons in the presence of CSPG but does not affect ErbB1−/− neurons. A: Cerebellar granule cells were cultured on
a control substrate or on a CSPG substrate, in the presence of PD168393 at the indicated concentrations. N=6 Two way ANOVA post hoc Bonferroni, * = pb0.05 when compared
to heterozygous cells on CSPG, *** = pb0.001 when compared to heterozygous cells on CSPG unless shown otherwise, # # # = pb0.001 when compared to heterozygous cells on
control substrate, ††=pb0.01 when compared to ErbB1−/− cells on control substrate. B: Representative images of cultured cerebellar granule neurons from an ErbB1−/− pup
and heterozygote littermates on polylysine/laminin substrates with or without 5 μg/ml CSPG ﬁxed and stained for neuron-speciﬁc β3 tubulin. The ErbB1 kinase inhibitor
PD168393 was present at 10 nM where indicated. Images were taken at ×20 magniﬁcation and scale bar equals 100 μm. The scale bar applies to all panels. C: Sensory neurons
were cultured on a control substrate or on a CSPG substrate, in the presence of PD168393 at the indicated concentrations. Neurite length was normalised to the control hetero-
zygous measurement. N=7. Two way ANOVA post hoc Bonferroni ** = pb0.01 and * = pb0.05 when compared to heterozygous cells under the same culture conditions unless
shown otherwise. # # = pb0.01 when compared to the control of the same genetic background. PD168393 rescues outgrowth from ErbB1-expressing neurons in the presence of
CSPG but does not affect ErbB1−/− neurons. D. Representative images of cultured sensory neurons from an ErbB1−/− pup and heterozygote littermates on polylysine/laminin
substrates with or without 5 μg/ml CSPG ﬁxed and stained for neuron-speciﬁc β3 tubulin. The ErbB1 kinase inhibitor PD168393 was present at 10 nM where indicated. Images
were taken at ×20 magniﬁcation and scale bar equals 100 μm. The scale bar applies to all panels.
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much more marked in cultures of cells expressing ErbB1 than in ErbB1
−/− cultures. Indeed, ﬁbrinogen at 0.5 μg/ml, and poly I:C, had no
detectable inhibitory effect on outgrowth from ErbB1 −/− cerebellar
granule neurons and sensory neurons, whilst CSPG had no detectable
inhibitory effect on outgrowth from ErbB1−/− sensory neurons. Mye-
lin, which contains multiple inhibitory factors, inhibited neurite out-
growth from ErbB1 −/− neurons of both types, although not as
strongly as from ErbB1 expressing neurons (Fig. 2; neurite length of
DRG cells on myelin was 28±4% and 52±11% of the length on polyly-
sine/laminin for+/− and−/− neurons respectively, N=5). Our results
strongly support the hypothesis that multiple inhibitors of neurite out-
growth act through the ErbB1 epidermal growth factor receptor
(Koprivica et al., 2005; Schachtrup et al., 2007).
Discussion
ErbB1 inhibitors offer a real hope of improving the regeneration of
axons in the injured CNS, but the role of ErbB1 in mediating theinhibition of neurite outgrowth has been challenged (Douglas et al.,
2009). We have used neurons from mice lacking ErbB1 to address this
question and have established unequivocally that ErbB1 is a critical me-
diator for a key group of cues that prevent axonal regeneration in the in-
jured brain and spinal cord: CNS myelin, CSPGs and ﬁbrinogen. In
contrast to a previous hypothesis (Douglas et al., 2009), we show that
the ErbB1 kinase inhibitors PD168393 and AG1478 rescue neurite out-
growth through their action on ErbB1 itself. We have also shown for
the ﬁrst time that the Toll-like receptor 3 agonist and viral mimic poly
I:C also inhibits axonal regeneration through a pathway involving calci-
um signalling upstream of ErbB1 activation.
The failure of axonal regeneration in the CNS of adult mammals is
believed to be partly the result of the presence of multiple inhibitors
of axonal growth both within CNS tissue and in and around lesion
sites in the CNS (Anderson et al., 2007). This is an attractive hypothesis,
not least because it should be possible to pharmacologically block the
receptors of such inhibitors. Unfortunately, blocking or genetically
deleting the known receptors for myelin proteins and CSPGs, or
blocking or eliminating speciﬁc inhibitors, despite encouraging early
Fig. 4. PD168393 rescues outgrowth in the presence of ﬁbrinogen from ErbB1 expressing neurons but does not affect ErbB1−/− neurons. A: Cerebellar granule cells were cultured
on a control substrate in the presence of ﬁbrinogen and/or PD168393 at the indicated concentrations. N=6. Two way ANOVA post hoc Bonferroni, ** = pb0.01. B: Representative
images of cultured cerebellar granule neurons from an ErbB1−/− pup and heterozygote littermates on polylysine/laminin substrates with or without ﬁbrinogen ﬁxed and stained
for neuron-speciﬁc β3 tubulin. The ErbB1 kinase inhibitor PD168393 was present at 10 nM where indicated. Images were taken at ×20 magniﬁcation and scale bar equals 100 μm.
The scale bar applies to all panels. C: Sensory neurons were cultured on a control substrate in the presence of ﬁbrinogen and/or PD168393 at the indicated concentrations. Neurite
length was normalised to the control heterozygous measurement. N=6. Two way ANOVA post hoc Bonferroni ** = pb0.01 when compared to heterozygous cells under the same
culture conditions unless shown otherwise, ## = pb0.01 when compared to neurons of the same genetic background on a control substrate. D: Representative images of cultured
sensory neurons from an ErbB1−/− pup and heterozygote littermates on polylysine/laminin substrates with or without ﬁbrinogen ﬁxed and stained for neuron-speciﬁc β3 tubulin.
The ErbB1 kinase inhibitor PD168393 was present at 10 nM where indicated. Images were taken at ×20 magniﬁcation and scale bar equals 100 μm. The scale bar applies to
all panels.
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produce reliable regeneration of CNS tracts (Steward et al., 2008;
Zheng et al., 2005). RhoA appeared to be an important target whose in-
hibition should block several axonal growth inhibitors but although
RhoA inhibitors have also been found in experiments by several labora-
tories to promote axonal regeneration in vivo, their efﬁcacy is relatively
modest (Bertrand et al., 2005; Boato et al., 2010; Fournier et al., 2003). It
is therefore important to identify further targets for pharmacological
intervention to promote axonal regeneration following CNS injury.
Viral infections during pregnancy are now believed to be important
sources of brain abnormalities (De Miranda et al., 2010; Meyer et al.,
2008) and subsequent behavioural problems (Brown and Derkits,
2010). Our ﬁndings indicate that the viral mimic poly I:C, an artiﬁcial
double stranded RNA, inhibits axonal elongation via calcium signalling
and ErbB1. This may help in the identiﬁcation of targets for interven-
tions to limit the effects of viral infections on the developing nervous
system. In addition, TLR3 may be activated by RNA released from dam-
aged mammalian cells (Kariko et al., 2005), which thereby constitute
another potentially inhibitory inﬂuence at CNS lesion sites, mediating
at least some of its effects through ErbB1.Although it is agreed that ErbB1 antagonists promote axonal growth
in the presence of otherwise inhibitory molecules (Koprivica et al.,
2005), two recent papers have suggested that the effect of the anti-
ErbB1 agents PD168393 and AG1478 in rescuing neurite outgrowth
on inhibitory substrates is due to their acting off-target rather than
directly on ErbB1 (Ahmed et al., 2009; Douglas et al., 2009). Our
results are incompatible with this view, since neither PD168393 nor
AG1478 improved neurite outgrowth from ErbB1−/− neurons under
any conditions. PD168393 and AG1478 were only able to improve
neurite outgrowth in cultures expressing ErbB1, conﬁrming that this
receptor is their critical site of action. It might be argued that, since
in a number of cases, inhibitory molecules failed to reduce neurite out-
growth from ErbB1−/− neurons, the fact that PD169393 and AG1478
did not then improve neurite outgrowth is not evidence that these
agents are acting through ErbB1 and not off-target. However, even
under conditions where ErbB1−/− neurons experienced a signiﬁcant
residual inhibition (cerebellar granule cells on CSPGs and myelin;
sensory neurons on myelin) PD169393 completely failed to rescue
neurite outgrowth. Themost likely explanation of the apparent discrep-
ancy between our results and those in the earlier papers (Ahmed et al.,
88 V.H.L. Leinster et al. / Experimental Neurology 239 (2013) 82–902009; Douglas et al., 2009) is that siRNA knockdown of ErbB1, used in
the previous studies, does not eliminate sufﬁcient ErbB1 to prevent its
function in limiting axonal regeneration in vitro.
Myelin proteins and CSPG are believed to be among the dominant
inhibitors of axonal regeneration operating around and within the
central nervous system lesion sites (Anderson et al., 2007; Sandvig
et al., 2004). It is therefore important to note that not all the inhibitory
effects of these agents can be attributed to ErbB1 activation. Both agentsretained signiﬁcant inhibitory activity in cultures lacking ErbB1. In
cultures expressing ErbB1, PD168393 was able to reverse all the
ErbB1-dependent component of inhibition, but the ErbB1-independent
component of inhibition remained (e.g. Figs. 2A, 3A). This is not surpris-
ing in view of the multiplicity of receptors involved (Anderson et al.,
2007). Ablating the known receptors for CSPGs does not eliminate all
inhibition mediated by those molecules (Dickendesher et al., 2012;
Shen et al., 2009). In addition, CNS myelin is known to contain several
89V.H.L. Leinster et al. / Experimental Neurology 239 (2013) 82–90inhibitors of axonal outgrowth including Sema 4D (Moreau-Fauvarque
et al., 2003). Semaphorins do not act through calcium signalling and
ErbB1 phosphorylation (Koprivica et al., 2005; Wen et al., 2004). Thus
ErbB1 inhibitors are likely to prove a component of a therapy for enhanc-
ing axonal regeneration following CNS injury rather than a stand-alone
treatment.
It is not yet clear how ErbB1 activation is brought about by CNS
myelin, ﬁbrinogen, CSPGs or poly I:C or how ErbB1 activation reduces
the ability of neurons to extend their axons. Autophosphorylation of
ErbB1 promotes cell survival and division in non-neuronal cells but
more recent work has shown that ErbB1 is the hub of a complex
web of inputs and outputs. Direct activating ligands include TGFα,
heparin-binding EGF (HB-EGF), betacellulin, amphiregulin, epiregulin
and SOCS2 (Adlkofer and Lai, 2000; Goldshmit et al., 2004) whilst
transactivation pathways allow G protein coupled receptors such as
the muscarinic acetylcholine receptor to activate ErbB1 (Zwick et al.,
1999). Less well understood pathways allow yet other classes of extra-
cellular ligands to activate ErbB1; for example components of the extra-
cellular matrix act through integrins to activate ErbB1 (Cabodi et al.,
2004). There is longstanding evidence that calcium is important in the
signalling from CNS myelin to bring about cessation of axonal growth
(Bandtlow et al., 1993; Loschinger et al., 1997). Koprivica et al. (2005)
found that calcium signalling was upstream of ErbB1 activation by
myelin and CSPGs. We have shown that calcium signalling is necessary
for ErbB1 activation and the inhibition of neurite outgrowth by poly I:C
in cultures expressing ErbB1. Taken together, these data suggest a
general mechanism in which calcium signals, elicited by a wide
range of cues (Gomez and Spitzer, 1999; Gomez and Zheng, 2006;
Lautermilch and Spitzer, 2000; Zheng and Poo, 2007), act via ErbB1 to
inhibit axon growth.
Once activated, ErbB1 has an enormous range of intracellular targets
in addition to the classical MAP kinase and protein kinase B pathways,
and can translocate to either the nucleus or mitochondria to act upon
substrates there (Demory et al., 2009; Lo, 2010). Although much
remains to be discovered about the mechanism of action of ErbB1 on
axonal regeneration our results show that ErbB1 is a negative regulator
of axonal outgrowth, they show that ErbB1 inhibitors act directly on
their primary target to enhance axonal regeneration, and they indicate
that ErbB1 inhibitors may prove an important component of multiva-
lent strategies for the restorative treatment of central nervous system
injury. Furthermore, the considerable knowledge of ErbB1 signalling
pathways gleaned from studies of cancer biology can now be applied
to enhancing axonal regeneration following spinal cord injury.
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